We are live on ! Find out more
ABMD

Abiomed Inc

Delisted

ABMD was delisted on the 21st of December, 2022.

529 hedge funds and large institutions have $17.9B invested in Abiomed Inc in 2018 Q3 according to their latest regulatory filings, with 71 funds opening new positions, 202 increasing their positions, 184 reducing their positions, and 63 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% more first-time investments, than exits

New positions opened: 71 | Existing positions closed: 63

12% more capital invested

Capital invested by funds: $16B → $17.9B (+$1.93B)

10% more repeat investments, than reductions

Existing positions increased: 202 | Existing positions reduced: 184

0% more funds holding

Funds holding: 527529 (+2)

5% less funds holding in top 10

Funds holding in top 10: 2120 (-1)

41% less call options, than puts

Call options by funds: $251M | Put options by funds: $424M

Holders
529
Holders Change
+2
Holders Change %
+0.38%
% of All Funds
12.09%
Holding in Top 10
20
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-4.76%
% of All Funds
0.46%
New
71
Increased
202
Reduced
184
Closed
63
Calls
$251M
Puts
$424M
Net Calls
-$173M
Net Calls Change
-$128M
Name Holding Trade Value Shares
Change
Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$2.09B +$103M +260,829 +6%
Primecap Management
2
Primecap Management
California
$1.52B -$74.9M -190,000 -5%
BlackRock
3
BlackRock
New York
$1.4B +$114M +290,298 +10%
State Street
4
State Street
Massachusetts
$779M +$78M +197,962 +13%
Renaissance Technologies
5
Renaissance Technologies
New York
$773M +$66.1M +167,600 +11%
BCM
6
Brown Capital Management
Maryland
$568M +$1.35M +3,435 +0.3%
AQR Capital Management
7
AQR Capital Management
Connecticut
$543M +$314M +796,482 +194%
Baillie Gifford & Co
8
Baillie Gifford & Co
United Kingdom
$362M -$513M -1,301,713 -62%
Franklin Resources
9
Franklin Resources
California
$332M +$16.6M +41,999 +6%
PAI
10
Palo Alto Investors
California
$319M -$71.5M -181,392 -20%
MWNA
11
Marshall Wace North America
New York
$310M +$84.6M +214,655 +45%
JIM
12
Jupiter Investment Management
United Kingdom
$287M +$230M +582,318 +1,030%
Bank of New York Mellon
13
Bank of New York Mellon
New York
$271M -$13.4M -33,869 -5%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$258M +$24.7M +62,701 +12%
FAM
15
Fred Alger Management
New York
$251M +$68.4M +173,466 +45%
Janus Henderson Group
16
Janus Henderson Group
United Kingdom
$233M +$96.7M +245,286 +90%
WRF
17
Waddell & Reed Financial
Kansas
$228M +$20.1M +51,007 +11%
Goldman Sachs
18
Goldman Sachs
New York
$210M +$38.3M +97,141 +26%
Norges Bank
19
Norges Bank
Norway
$203M +$16.2M +40,987 +10%
Sands Capital Management
20
Sands Capital Management
Virginia
$200M +$175M +443,607 New
Northern Trust
21
Northern Trust
Illinois
$199M +$234K +593 +0.1%
Invesco
22
Invesco
Georgia
$196M -$5.5M -13,961 -3%
Fidelity Investments
23
Fidelity Investments
Massachusetts
$193M -$103M -262,183 -38%
Deutsche Bank
24
Deutsche Bank
Germany
$182M +$22.7M +57,544 +17%
Two Sigma Advisers
25
Two Sigma Advisers
New York
$180M -$83.2M -211,100 -35%

ABMD Hedge Fund Activity: Q3 2018 in Review

529 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Abiomed Inc (ABMD) for Q3 2018, worth a combined $17.9B — up 12% from $16B a quarter earlier.

Buyers outnumbered sellers: 71 funds opened new ABMD positions and 63 closed out — a net gain of 8 holders — while 202 added to existing stakes and 184 trimmed.

The largest buyer was AQR Capital Management, adding an estimated $314M. The largest seller was Baillie Gifford & Co, cutting an estimated $513M.

  • 529 institutional investors held Abiomed Inc (ABMD) as of Q3 2018, up from 527 in Q2 2018.
  • Funds reported $17.9B of Abiomed Inc stock for Q3 2018, up 12% quarter-over-quarter.
  • 71 funds opened new Abiomed Inc positions in Q3 2018 and 63 closed out, a net change of +8 holders.
  • The largest Abiomed Inc buyer in Q3 2018 was AQR Capital Management, an estimated $314M added.
  • The largest Abiomed Inc seller in Q3 2018 was Baillie Gifford & Co, an estimated $513M sold.

Based on aggregated 13F filings for Q3 2018.